Penumbra, Inc. (PEN)

Over the past six months, Penumbra's stock has experienced mixed performance, with a 1-year total shareholder return of 24.78%. In Q4 2025, Penumbra reported adjusted EPS of $1.18 and revenues of $385.4 million, surpassing estimates, although the stock lost about 1.6% the following month. The FTC issued a Second Request to Penumbra and Boston Scientific regarding a merger review in March 2026. As of late March 2026, Penumbra had a consensus rating of "Hold" with an average price target of $361.69.

The provided search results do not contain specific information regarding the demand seasonality for Penumbra, Inc.'s products and services. Generally, the medical device industry benefits from recurring needs for devices and growing global demand for advanced treatments, which can provide stability. However, this does not directly address specific seasonal fluctuations in demand.

Penumbra, Inc., founded in 2004 and headquartered in Alameda, California, is a global healthcare company specializing in medical devices for neuro and peripheral vascular markets. The company develops technologies for conditions like stroke, aneurysm, and thromboembolism. Its product portfolio includes thrombectomy devices like the Penumbra System and Indigo System, embolization and access devices such as the Penumbra Coil and Ruby Embolization Platform, neurosurgical tools like the Artemis Neuro Evacuation Device, and immersive healthcare technologies through MVI Health.

Penumbra operates globally, selling products through direct sales in the United States, most of Europe, Canada, and Australia, and through distributors in other international markets. The company has operations in countries such as the US, Brazil, Germany, Australia, Canada, Singapore, France, and the UK. The United States generates the maximum revenue, followed by international markets, and Penumbra is expanding into international markets, including constructing a new manufacturing facility in Costa Rica.

Information specifically detailing Penumbra's brand reputation in the past year is not explicitly available. However, historical criticisms and recalls have been noted. In 2016, a lawsuit claimed the Penumbra Coil 400 caused brain damage. The company's specialized catheter has been linked to patient deaths and was a target of stock short sellers in 2020, leading to requests for investigations by the SEC and U.S. Food and Drug Administration. Recalls include the Penumbra Coil 400 in 2011, a 3D revascularization device in 2017, and a catheter used during heart surgery in 2020 due to increased risk of mortality and serious injury.

Penumbra's ownership is distributed among institutional investors (63.90%), insiders (3.07%), and public companies and individual investors (33.02%). Institutional ownership is high, at 88.88%. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. The largest individual shareholder is Walter Charles Wang, owning 3.78% of the company.